← Back to headlines
Morgan Stanley Raises Eli Lilly Price Target on Updated Biopharma Model
Morgan Stanley has increased its price target for Eli Lilly and Company (LLY), based on updated assumptions within its biopharma financial model.
17 Apr, 13:38 — 17 Apr, 13:38
Sources
Showing 1 of 1 sources
Related Stories
Nvidia Backs OpenAI's Ohio Data Center Project with $105 Billion Guarantee
6m ago
Einride to Deploy 500 Tesla Electric Trucks for North American Fleet
20m ago
China's Top Envoy to Visit Seoul Amid Shifting US-South Korea Ties
30m ago
Low Danube Water Levels Threaten Paks Nuclear Power Plant Operations
36m ago